Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Beam Therapeutics Inc shares valued at $104,122 were sold by Bellon Christine on Apr 01 ’25. At $18.35 per share, Bellon Christine sold 5,674 shares. The insider’s holdings dropped to 117,294 shares worth approximately $2.01 million following the completion of this transaction.
Also, Evans John M. sold 30,663 shares, netting a total of over 562,684 in proceeds. Following the sale of shares at $18.35 each, the insider now holds 986,249 shares.
Before that, Ciaramella Giuseppe had sold 7,434 shares from its account. In a trade valued at $136,418, the President traded Beam Therapeutics Inc shares for $18.35 each. Upon closing the transaction, the insider’s holdings decreased to 7,434 shares, worth approximately $3.26 million.
As published in a research note from BofA Securities on March 28, 2025, Beam Therapeutics Inc [BEAM] has been rated up from a Neutral to a Buy and the price target has been revised to $42. Analysts at Scotiabank upgraded the stock from ‘”a Sector perform”‘ to ‘”a Sector outperform”‘ outlook in a report released in early March. As of January 29, 2025, Cantor Fitzgerald has increased its “Neutral” rating to a “an Overweight” for BEAM. Earlier on November 06, 2024, Leerink Partners upgraded its rating. Their new recommendation was “an Outperform” for BEAM stock which previously was a “a Market perform”.
Analyzing BEAM Stock Performance
On last trading session,, Beam Therapeutics Inc [NASDAQ: BEAM] rose 2.27% to $17.14. The stock’s lowest price that day was $16.49, but it reached a high of $17.225 in the same session. During the last five days, there has been a surge of approximately 0.88%. Over the course of the year, Beam Therapeutics Inc shares have dropped approximately -30.97%. Shares of the company reached a 52-week high of $35.25 on 02/18/25 and a 52-week low of $13.52 on 04/07/25.
Support And Resistance Levels for Beam Therapeutics Inc (BEAM)
According to the 24-hour chart, there is a support level at 16.68, which, if violated, would cause prices to drop to 16.21. In the upper region, resistance lies at 17.42. The next price resistance is at 17.69. RSI (Relative Strength Index) is 48.68 on the 14-day chart, showing neutral technical sentiment.
Is Beam Therapeutics Inc subject to short interest?
Stocks of Beam Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.89 million shares to 21.73 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 20.84 million shares. A jump of 4.08% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.99 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.99.
Which companies own the most shares of Beam Therapeutics Inc (BEAM)?
In terms of Beam Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 37 in the next 12 months, up nearly 120.76% from the previous closing price of $16.76. Analysts anticipate Beam Therapeutics Inc stock to reach 55 by 2025, with the lowest price target being 25. In spite of this, 6 analysts ranked Beam Therapeutics Inc stock as Buy at the end of 2025.
